Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ga-DPI-4452
- Development stage
- Unknown
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Ga-DPI-4452 (also known as ITM-94 or Debio 0328) is a first-in-class, gallium-68-radiolabeled cyclic peptide (peptidomimetic) that acts as a diagnostic positron emission tomography (PET) imaging agent. It targets Carbonic Anhydrase IX (CAIX), a cell-surface glycoprotein that is highly overexpressed in hypoxic tumors and clear cell renal cell carcinoma (ccRCC) but has restricted expression in healthy tissues. Ga-DPI-4452 forms a theranostic pair with its therapeutic counterpart, [177Lu]Lu-DPI-4452 (ITM-91), which is radiolabeled with lutetium-177 for targeted radionuclide therapy. Originally discovered by 3B Pharmaceuticals, the theranostic pair was licensed to Debiopharm and subsequently exclusively licensed to ITM Isotope Technologies Munich in September 2024. Ga-DPI-4452 is currently in Phase 1/2 clinical development for the detection and staging of ccRCC, indeterminate renal masses, and other CAIX-expressing solid tumors, including colorectal cancer and pancreatic ductal adenocarcinoma.
- Other names
- 68Ga-DPI-4452[68Ga]Ga-DPI-4452CA-IX peptidegallium Ga 68 DPI-4452gallium-68 DPI-4452gallium68 DPI-4452gallium 68 DPI-4452
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on Ga-DPI-4452.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ga-DPI-4452.